A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemia
J. L. Marin-Rubio, R. E. Heap, T. Heunis, M. E. Duenas, J. Inns, J. Scott, A. J. Simpson, J. M. Allan, H. Blair, O. Heidenreich, B. Saxty, M. Trost
This study identifies nilotinib as an anti-inflammatory drug using a MALDI-TOF assay in AML-derived monocytes, showing it inhibits the p38-MK2/3 signaling axis.
bioRxiv · Mar 29, 2021 · PreprintCancer Biology